They?
Hi Tech,
Your comments âmintedâ and highly âsuccessful businessesâ caught my eye.
Do you have any further details on these businesses as all I can come up with is that The Behnke Group has a turnover of circa $5m and is in the 2-10 employee classification. From my POV, the value in the Ciz Bio tie-up is Billâs industry knowledge and contacts which would include potential access to $$.
Cheers
VV
OAP,
Agreed.
I read the RNS a few times this morning and then let it sink in whilst going about my business.
My thinking is that whilst the royalty figure is less than the previous 15% I feel that this is more than offset by the 10% stake in Cizzle Bio. My view is that in the event that the test takes off then at some point Cizzle Bio would float on Nasdaq where biotech companies with a proven disruptive product are priced more favourably than similar companies on LSE.
The guaranteed income also removes the need to worry about fundraising whilst Cizzle Bio get on with developing the test for market, allowing AS to concentrate on finding a partner for European rollout.
I also wouldnât rule out further relationship building with Bio-Techne, particularly when it comes to China.
All in all, Iâm viewing this news as positive and so I added some more today.
VV
Looking at the trades, those that wanted to get out after the previous RNS are taking their opportunity today.
So thatâs why we only raised 600k.
Letâs see if there is a broader explanation of this deal in his next interview.
Good morning all. I hope you all had a good Easter weekend with family and friends.
neilin, the information that you provide on this board is invaluable. Your posts also come across as calculated in the sense of accuracy and conformity of certain boundaries.
The fact that youâve thrown a new and previously unheard of âboneâ into the ring, piqued my interest.
Could you elaborate on this project please?
VV
After reading todays RNS and comparing it to the RNS in September, I feel a little hoodwinked.
I guess Iâve only myself to blame for settling in to the collective mantra of patience is the key.
I contributed to the âNext RNSâ thread on 18th March. My view was that given previous announcements, the next RNS should be clinical trial results.
This was also based on the assertions from AS that he wouldnât RNS fluff.
To receive this news this morning after a 6mth news blackout was a bit of a shock and disappointed would be understating it.
It was stated back in September that key milestones had been met to begin clinical trials following the completion of trials design. Clearly todays news conflicts with that claim.
For the avoidance of doubtâŚ
âOn 10 August 2023 the Group announced an expansion of its research programme with the University of York to. This followed significant further progress in isolating additional new and specific monoclonal antibodies to the CIZ1B biomarker and incorporating these into a new high-throughput clinical diagnostic immunoassay platform. The recent developments meet key milestones to begin commercial clinical trials. The Company is now engaged in clinical trials design to support the validation and accreditation of the CIZ1B test prior to commercial launch.â
VV
Thanks OAP.
Just watched it.
Frankly, I donât know why AS bothered. No reason given for the switch.
Does anybody have a link for the interview.
For some reason I canât find it after numerous searches.
Cheers
VV
Iâm busy today, just as well because what Iâd post right now wouldnât be pretty.
The phase 1 trial results were hardly exciting.
I wonder if this was the same trial.
Phase 1.
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-a-vaccine-called-ast-vac2-for-non-small-cell-lung-cancer
Summary of results.
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-a-vaccine-called-ast-vac2-for-non-small-cell-lung-cancer#undefined
Gary Middleton
https://www.birmingham.ac.uk/staff/profiles/immunology-immunotherapy/middleton-gary
A very telling post hinting at the future ownership of this as weâve all suspected.
I wouldnât say that the new CEO of Cizzle inc is fluff.
Our trader from yesterday having another go today?
Hi Brondby,
Iâm rather hoping that they are near complete on the clinical testing given that they stated the following nearly 6 months agoâŚ
âOn 10 August 2023 the Group announced an expansion of its research programme with the University of York to. This followed significant further progress in isolating additional new and specific monoclonal antibodies to the CIZ1B biomarker and incorporating these into a new high-throughput clinical diagnostic immunoassay platform. The recent developments meet key milestones to begin commercial clinical trials. The Company is now engaged in clinical trials design to support the validation and accreditation of the CIZ1B test prior to commercial launch.â
Looks like somebody wants out.
I posted the following on here 17th Jan after watching their webinarâŚ
Iâve just watched their webinar.
Theyâre 6mths behind setting up a cohesive sales structure. Theyâll need additional funding in the near term due to this and their less than satisfactory product uptake.
BNN Breaking is a news website based in Hong Kong launched in 2022 by Indian-American entrepreneur Gurbaksh Chahal. It has been criticised for posting a number of misleading and inaccurate news stories, potentially using AI-driven content aggregation.